Question from Deputy Ken O'Flynn - PQ 36654-26
Deputy O'Flynn asked if any assessment has been carried out regarding the projected impact of obesity-related disease. Read the HSE response.
- Published date:
- :
Browse and read HSE's latest publications, which include strategic plans, reports, official policies and codes, Parliamentary Question (PQ) responses, and board meeting minutes.
Deputy O'Flynn asked if any assessment has been carried out regarding the projected impact of obesity-related disease. Read the HSE response.
Deputy O'Flynn asked about the most common categories of rejected pharmacy claims under the General Medical Services Scheme. Read the HSE response.
Deputy O'Flynn asked about the public communication on manganese contamination in drinking water. Read the HSE response.
Deputy O'Flynn asked about assessments carried out prior to the Steri-neb Salamol price uplift. Read the HSE response.
Deputy O'Flynn asked about the reimbursement price uplift granted to Steri-neb Salamol 2.5mg/2.5ml in 2022. Read the HSE response.
Deputy O'Flynn asked if obesity-related disease expenditure is separately identifiable within the HSE budgeting process. Read the HSE response.
Deputy O'Flynn asked about an assessment of the financial or operational impact of rejected pharmacy claims on community pharmacies. Read the HSE response.
Deputy O'Flynn asked how many medicinal products received reimbursement price uplifts under PCRS arrangements from 2020 to 2026. Read the HSE response.
Deputy O'Flynn asked if any national procurement framework exists governing the engagement of private ambulance providers by HSE-funded hospitals.
Deputy O'Flynn asked about the administrative or submission errors resulting in rejected or unpaid pharmacy claims. Read the HSE response.